Targeted a-Therapy in Prostate Cancer
- Conditions
- Prostate cancer.Malignant neoplasm of prostate
- Registration Number
- IRCT20210612051548N1
- Lead Sponsor
- Boushehr University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 10
Patients must have had progressive metastatic castration-resistant prostate cancer.
Patients must have a positive 68Ga-PSMA-11 PET/CT scan.
Patients must have recovered or stabilized to = Grade 2 from all clinically significant toxicities related to prior prostate cancer therapy.
Patients must have an ECOG performance status of 0 to 2.
Previous treatment with Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223 or hemi-body irradiation or previous PSMA-targeted radioligand therapy.
The patient was diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment (Patients with a prior history of malignancy who have been disease-free for more than 3 years are eligible).
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method